Quantitative optical mapping of two-dimensional materials

The pace of two-dimensional materials (2DM) research has been greatly accelerated by the ability to identify exfoliated thicknesses down to a monolayer from their optical contrast. Since this process requires time-consuming and error-prone manual assignment to avoid false-positives from image features with similar contrast, efforts towards fast and reliable automated assignments schemes is essential. We show that by modelling the expected 2DM contrast in digitally captured images, we can automatically identify candidate regions of 2DM. More importantly, we show a computationally-light machine vision strategy for eliminating false-positives from this set of 2DM candidates through the combined use of binary thresholding, opening and closing filters, and shape-analysis from edge detection. Calculation of data pyramids for arbitrarily high-resolution optical coverage maps of two-dimensional materials produced in this way allows the real-time presentation and processing of this image data in a zoomable interface, enabling large datasets to be explored and analysed with ease. The result is that a standard optical microscope with CCD camera can be used as an analysis tool able to accurately determine the coverage, residue/contamination concentration, and layer number for a wide range of presented 2DMs

Stellar multiplicity: an interdisciplinary nexus

Our uncertainties about binary star systems (and triples and so on) limit our capabilities in literally every single one of the Thematic Areas identified for Astro2020. We need to understand the population statistics of stellar multiplicity and their variations with stellar type, chemistry, and dynamical environment: Correct interpretation of any exoplanet experiment depends on proper treatment of resolved and unresolved binaries; stellar multiplicity is a direct outcome of star and companion formation; the most precise constraints on stellar structure come from well-characterized binary systems; stellar populations heavily rely on stellar and binary evolution modeling; high-redshift galaxy radiation and reionization is controlled by binary-dependent stellar physics; compact objects are the outcomes of binary evolution; the interpretation of multi-messenger astronomy from gravitational waves, light, and neutrinos relies on understanding the products of binary star evolution; near-Universe constraints on the Hubble constant with Type Ia supernovae and gravitational-wave mergers are subject to systematics related to their binary star progenitors; local measures of dark-matter substructure masses are distorted by binary populations. In order to realize the scientific goals in each of these themes over the next decade, we therefore need to understand how binary stars and stellar multiplets are formed and distributed in the space of masses, composition, age, and orbital properties, and how the distribution evolves with time. This white paper emphasizes the interdisciplinary importance of binary-star science and advocates that coordinated investment from all astrophysical communities will benefit almost all branches of astrophysics.Comment: Submitted to the Astro2020 Decadal Survey White Paper cal

No Massive Companion to the Coherent Radio-Emitting M Dwarf GJ 1151

The recent detection of circularly polarized, long-duration (>8 hr) low-frequency (~150 MHz) radio emission from the M4.5 dwarf GJ 1151 has been interpreted as arising from a star-planet interaction via the electron cyclotron maser instability. The existence or parameters of the proposed planets have not been determined. Using 20 new HARPS-N observations, we put 99th-percentile upper limits on the mass of any close companion to GJ 1151 at Msini < 5.6 M earth. With no stellar, brown dwarf, or giant planet companion likely in a close orbit, our data are consistent with detected radio emission emerging from a magnetic interaction between a short-period terrestrial-mass planet and GJ 1151

Carbon-Enhanced Metal-Poor star candidates from BP/RP Spectra in GaiaGaia DR3

Carbon-enhanced metal-poor (CEMP) stars comprise almost a third of stars with [Fe/H] < --2, although their origins are still poorly understood. It is highly likely that one sub-class (CEMP-$s$ stars) is tied to mass-transfer events in binary stars, while another sub-class (CEMP-no stars) are enriched by the nucleosynthetic yields of the first generations of stars. Previous studies of CEMP stars have primarily concentrated on the Galactic halo, but more recently they have also been detected in the thick disk and bulge components of the Milky Way. $Gaia$ DR3 has provided an unprecedented sample of over 200 million low-resolution ($R\approx$ 50) spectra from the BP and RP photometers. Training on the CEMP catalog from the SDSS/SEGUE database, we use XGBoost to identify the largest all-sky sample of CEMP candidate stars to date. In total, we find 58,872 CEMP star candidates, with an estimated contamination rate of 12%. When comparing to literature high-resolution catalogs, we positively identify 60-68% of the CEMP stars in the data, validating our results and indicating a high completeness rate. Our final catalog of CEMP candidates spans from the inner to outer Milky Way, with distances as close as $r \sim$ 0.8 kpc from the Galactic center, and as far as $r >$ 30 kpc. Future higher-resolution spectroscopic follow-up of these candidates will provide validations of their classification and enable investigations of the frequency of CEMP-$s$ and CEMP-no stars throughout the Galaxy, to further constrain the nature of their progenitors.Comment: 19 pages, 14 figures, accepted to MNRA

Catalyst Interface Engineering for Improved 2D Film Lift-Off and Transfer

The mechanisms by which chemical vapor deposited (CVD) graphene and hexagonal boron nitride (h-BN) films can be released from a growth catalyst, such as widely used copper (Cu) foil, are systematically explored as a basis for an improved lift-off transfer. We show how intercalation processes allow the local Cu oxidation at the interface followed by selective oxide dissolution, which gently releases the 2D material (2DM) film. Interfacial composition change and selective dissolution can thereby be achieved in a single step or split into two individual process steps. We demonstrate that this method is not only highly versatile but also yields graphene and h-BN films of high quality regarding surface contamination, layer coherence, defects, and electronic properties, without requiring additional post-transfer annealing. We highlight how such transfers rely on targeted corrosion at the catalyst interface and discuss this in context of the wider CVD growth and 2DM transfer literature, thereby fostering an improved general understanding of widely used transfer processes, which is essential to numerous other applications.We acknowledge funding from the ERC (InsituNANO, grant 279342). R.W. acknowledges an EPSRC Doctoral Training Award (EP/M506485/1). During this work, S.T. was supported in parts by a DFG research fellowship under grant TA 1122/1-1:1. J.A.A.-W. acknowledges a Research Fellowship from Churchill College, Cambridge. Z.A.V.V. acknowledges funding from ESPRC grant EP/L016087/1. P.B. and B.S.J. thank the Danish National Research Foundation Centre for Nanostructured graphene, DNRF103, and EU Horizon 2020 “Graphene Flagship” 696656. T.J.B. and P.R.W. acknowledge financial support from EU FP7-6040007 “GLADIATOR” and Innovation Fund Denmark Da-Gate 0603-005668B. P.R.K. acknowledges a Lindemann Trust Fellowship

Stellar Astrophysics and Exoplanet Science with the Maunakea Spectroscopic Explorer (MSE)

The Maunakea Spectroscopic Explorer (MSE) is a planned 11.25-m aperture facility with a 1.5 square degree field of view that will be fully dedicated to multi-object spectroscopy. A rebirth of the 3.6m Canada-France-Hawaii Telescope on Maunakea, MSE will use 4332 fibers operating at three different resolving powers (R ~ 2500, 6000, 40000) across a wavelength range of 0.36-1.8mum, with dynamical fiber positioning that allows fibers to match the exposure times of individual objects. MSE will enable spectroscopic surveys with unprecedented scale and sensitivity by collecting millions of spectra per year down to limiting magnitudes of g ~ 20-24 mag, with a nominal velocity precision of ~100 m/s in high-resolution mode. This white paper describes science cases for stellar astrophysics and exoplanet science using MSE, including the discovery and atmospheric characterization of exoplanets and substellar objects, stellar physics with star clusters, asteroseismology of solar-like oscillators and opacity-driven pulsators, studies of stellar rotation, activity, and multiplicity, as well as the chemical characterization of AGB and extremely metal-poor stars.Comment: 31 pages, 11 figures; To appear as a chapter for the Detailed Science Case of the Maunakea Spectroscopic Explore

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

BACKGROUND The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score based on a 21-gene assay to determine the risk of recurrence. Whether the level of clinical risk of breast cancer recurrence adds prognostic information to the recurrence score is not known. METHODS We performed a prospective trial involving 9427 women with hormone-receptor–positive, human epidermal growth factor receptor 2–negative, axillary node–negative breast cancer, in whom an assay of 21 genes had been performed, and we classified the clinical risk of recurrence of breast cancer as low or high on the basis of the tumor size and histologic grade. The effect of clinical risk was evaluated by calculating hazard ratios for distant recurrence with the use of Cox proportional-hazards models. The initial endocrine therapy was tamoxifen alone in the majority of the premenopausal women who were 50 years of age or younger. RESULTS The level of clinical risk was prognostic of distant recurrence in women with an intermediate 21-gene recurrence score of 11 to 25 (on a scale of 0 to 100, with higher scores indicating a worse prognosis or a greater potential benefit from chemotherapy) who were randomly assigned to endocrine therapy (hazard ratio for the comparison of high vs. low clinical risk, 2.73; 95% confidence interval [CI], 1.93 to 3.87) or to chemotherapy plus endocrine (chemoendocrine) therapy (hazard ratio, 2.41; 95% CI, 1.66 to 3.48) and in women with a high recurrence score (a score of 26 to 100), all of whom were assigned to chemoendocrine therapy (hazard ratio, 3.17; 95% CI, 1.94 to 5.19). Among women who were 50 years of age or younger who had received endocrine therapy alone, the estimated (±SE) rate of distant recurrence at 9 years was less than 5% (≤1.8±0.9%) with a low recurrence score (a score of 0 to 10), irrespective of clinical risk, and 4.7±1.0% with an intermediate recurrence score and low clinical risk. In this age group, the estimated distant recurrence at 9 years exceeded 10% among women with a high clinical risk and an intermediate recurrence score who received endocrine therapy alone (12.3±2.4%) and among those with a high recurrence score who received chemoendocrine therapy (15.2±3.3%). CONCLUSIONS Clinical-risk stratification provided prognostic information that, when added to the 21-gene recurrence score, could be used to identify premenopausal women who could benefit from more effective therapy

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

BACKGROUND The recurrence score based on the 21-gene breast cancer assay predicts chemotherapy benefit if it is high and a low risk of recurrence in the absence of chemotherapy if it is low; however, there is uncertainty about the benefit of chemotherapy for most patients, who have a midrange score. METHODS We performed a prospective trial involving 10,273 women with hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative, axillary node–negative breast cancer. Of the 9719 eligible patients with follow-up information, 6711 (69%) had a midrange recurrence score of 11 to 25 and were randomly assigned to receive either chemoendocrine therapy or endocrine therapy alone. The trial was designed to show noninferiority of endocrine therapy alone for invasive disease–free survival (defined as freedom from invasive disease recurrence, second primary cancer, or death). RESULTS Endocrine therapy was noninferior to chemoendocrine therapy in the analysis of invasive disease–free survival (hazard ratio for invasive disease recurrence, second primary cancer, or death [endocrine vs. chemoendocrine therapy], 1.08; 95% confidence interval, 0.94 to 1.24; P=0.26). At 9 years, the two treatment groups had similar rates of invasive disease–free survival (83.3% in the endocrine-therapy group and 84.3% in the chemoendocrine-therapy group), freedom from disease recurrence at a distant site (94.5% and 95.0%) or at a distant or local–regional site (92.2% and 92.9%), and overall survival (93.9% and 93.8%). The chemotherapy benefit for invasive disease–free survival varied with the combination of recurrence score and age (P=0.004), with some benefit of chemotherapy found in women 50 years of age or younger with a recurrence score of 16 to 25. CONCLUSIONS Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with hormone-receptor–positive, HER2-negative, axillary node–negative breast cancer who had a midrange 21-gene recurrence score, although some benefit of chemotherapy was found in some women 50 years of age or younger